The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.
Joyce Liu
No relevant relationships to disclose
William Thomas Barry
No relevant relationships to disclose
Michael J. Birrer
No relevant relationships to disclose
Jung-min Lee
No relevant relationships to disclose
Ronald J. Buckanovich
No relevant relationships to disclose
Gini F. Fleming
No relevant relationships to disclose
BJ Rimel
No relevant relationships to disclose
Mary K. Buss
No relevant relationships to disclose
Sreenivasa R. Nattam
No relevant relationships to disclose
Jean Hurteau
No relevant relationships to disclose
Weixiu Luo
No relevant relationships to disclose
Philippa Quy
No relevant relationships to disclose
Elizabeth Obermayer
No relevant relationships to disclose
Christin Whalen
No relevant relationships to disclose
Hang Lee
No relevant relationships to disclose
Eric P. Winer
No relevant relationships to disclose
Elise C. Kohn
No relevant relationships to disclose
S. Percy Ivy
No relevant relationships to disclose
Ursula Matulonis
No relevant relationships to disclose